has function has role vaccinated in route immunizes against disease immunizes recipient brain cancer Homo sapiens subcutaneous route therapeutic vaccine function vaccine in clinical trial role brain cancer vaccine DIPG and GMB Immunomodulatory DC vaccine 6301 Hayleigh Kahn NCT: https://clinicaltrials.gov/study/NCT03914768 cancer vaccine VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6301 Jie Zheng A cancer vaccine based on ex vivo genetic modifications in combination with known tumor-specific antigens may substantially enhance the activation potential of tumor-specific T cells with improved benefit to patients. This DC vaccine is based on autologous DCs pulsed with genetically modified tumor cells or related antigens such as neoantigens to induce a strong anti-tumor immunity. The patient will receive intravenous cyclophosphamide (200 mg/m2) or oral (cytoxan) before the vaccine, followed by DC vaccine and intravenous bevacizumab (15 mg/kg). therapeutic cancer vaccine whole cell cancer vaccine